Oncology Bytes - First Line Treatment Patterns in mRCC – Dr Anupama Vijay | IUCS 2024

🗓️ Register for IUCS 2025: https://urologycancersummit.org/regis... 🎥 Oncology Bytes – IUCS 2024 In this episode, Dr. Anupama Vijay, medical oncology registrar at Leicester Royal Infirmary, shares real-world data from a UK-based study on first-line treatment patterns and progression in metastatic renal cell carcinoma (mRCC). 📊 The study tracked 131 patients from 2019 to 2024, analyzing clinical choices, survival outcomes, and access to second-line therapy. 🔍 Key findings: Ipilimumab/Nivolumab was the most common first-line therapy (26%), followed by Avelumab/Axitinib and Pazopanib Median progression-free survival (PFS) for favorable/intermediate risk patients was ~13.7 months Only 64% of patients who progressed on first-line therapy received second-line treatment Highlights a significant drop-off rate and the need for early access to effective combinations This audit echoes broader concerns across the UK regarding second-line access in mRCC and supports aggressive first-line treatment planning. 📄 Read the full abstract: https://urologycancersummit.org/exter... 🌐 Learn more at: https://oncoassist.com/ --------------------------------------------------- 📲 Oncology at your fingertips. Download the ONCOassist app: 📥 iOS: https://apple.co/4iuMxfS 📥 Android: https://bit.ly/oncoassistonandroid 🚀 SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights! 🔔 Turn on notifications so you never miss an episode. 📌 FOLLOW US FOR UPDATES: 📍 LinkedIn: https://bit.ly/oncoassistlinkedin 📍 Twitter/X: https://bit.ly/oncoassisttwitter #OncologyBytes #IUCS2024 #mRCC #RealWorldData #UKOncology #RenalCancer #CheckpointInhibitors #SecondLineAccess #Oncoassist #CancerCareAudit #FirstLineTherapy #Oncoalert